The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.

Samsung Biologics (KRX: 207940.KS) announced that it has reached an agreement with Biogen for the buyout of Biogen�s stake in the Samsung Bioepis joint venture for USD $2.3 billion. The transaction is expected to boost earnings growth of Samsung Biologics on a consolidated basis, fully capitalizing on Samsung Bioepis� growth outlook.

A new technology that uses bio-printed �patches� to repair damaged heart tissue has been proven to be safer and more cost-effective for patients.

The U.S. Food and Drug Administration has approved a new indication for?Cytalux (pafolacianine) to assist surgeons in identifying lung cancer lesions in adult patients with known or suspected lung cancer.